200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
Canada
604 336 7906
https://www.aequuspharma.ca
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Douglas Glen Janzen | Chairman, CEO & President | 206,25k | N/A | 1969 |
Ms. Ann Fehr CGA, CPA | CFO & Corporate Secretary | 136,13k | N/A | 1969 |
Mr. Grant Larsen | Chief Commercial Officer | 244,58k | N/A | N/A |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Aequus Pharmaceuticals Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.